TY - JOUR
T1 - Paclitaxel-loaded Pluronic nanoparticles formed by a temperature-induced phase transition for cancer therapy
AU - Oh, Keun Sang
AU - Song, Ji Yung
AU - Cho, Sun Hang
AU - Lee, Bum Suk
AU - Kim, Sang Yoon
AU - Kim, Kwangmeyung
AU - Jeon, Hyesung
AU - Kwon, Ick Chan
AU - Yuk, Soon Hong
N1 - Funding Information:
This work was financially supported by the Ministry of Science and Technology ( 2009K001600 , 2009K001602 , and 2009K001593 ) and by a grant from the fundamental R&D program for core technology of materials funded by the Ministry of Knowledge Economy ( K00060-282 ), Republic of Korea.
PY - 2010/12/20
Y1 - 2010/12/20
N2 - We prepared nanoparticles by a temperature-induced phase transition in a mixture of Pluronic F-68 and liquid PEG (polyethylene glycol, molecular weight: 400) containing paclitaxel (PTX) with a fast, simple, continuous and solvent-free process. The liquid PEG is used as solubilizer of PTX and the polymer for the encapsulation of PTX is composed of Pluronic F-68. At the phase transition temperature, the polymer mixture was changed to the liquid phase, and stirring the liquid polymer mixture formed emulsions composed of PEG containing PTX and liquidized Pluronic F-68. On the nanometer scale, PEG containing PTX was encapsulated by Pluronic F-68 by cooling to 0 °C to form Pluronic nanoparticles. The morphology and size distribution of the prepared Pluronic nanoparticles were observed using FE-SEM and TEM, and a particle size analyzer and cryo-TEM were used to observe the shape of paclitaxel-loaded Pluronic nanoparticles in an aqueous state. To apply Pluronic nanoparticles as a delivery system for cancer therapy, the release pattern of PTX, a model anti-cancer drug, was observed and the tumor growth was monitored by injecting the PTX-loaded Pluronic nanoparticles into the tail veins of tumor-bearing mice. We also evaluated the time-dependent excretion profile, in vivo biodistribution, circulation time, and tumor targeting ability of PTX-loaded Pluronic nanoparticles using non-invasive live animal imaging technology. In the early stage within 7 h of release, the loaded PTX was rapidly released and the sustained release was observed for up to 48 h. In vivo studies, PTX-loaded Pluronic nanoparticles were observed with higher anti-tumor efficacy compared with PTX formulated in Cremophor EL.
AB - We prepared nanoparticles by a temperature-induced phase transition in a mixture of Pluronic F-68 and liquid PEG (polyethylene glycol, molecular weight: 400) containing paclitaxel (PTX) with a fast, simple, continuous and solvent-free process. The liquid PEG is used as solubilizer of PTX and the polymer for the encapsulation of PTX is composed of Pluronic F-68. At the phase transition temperature, the polymer mixture was changed to the liquid phase, and stirring the liquid polymer mixture formed emulsions composed of PEG containing PTX and liquidized Pluronic F-68. On the nanometer scale, PEG containing PTX was encapsulated by Pluronic F-68 by cooling to 0 °C to form Pluronic nanoparticles. The morphology and size distribution of the prepared Pluronic nanoparticles were observed using FE-SEM and TEM, and a particle size analyzer and cryo-TEM were used to observe the shape of paclitaxel-loaded Pluronic nanoparticles in an aqueous state. To apply Pluronic nanoparticles as a delivery system for cancer therapy, the release pattern of PTX, a model anti-cancer drug, was observed and the tumor growth was monitored by injecting the PTX-loaded Pluronic nanoparticles into the tail veins of tumor-bearing mice. We also evaluated the time-dependent excretion profile, in vivo biodistribution, circulation time, and tumor targeting ability of PTX-loaded Pluronic nanoparticles using non-invasive live animal imaging technology. In the early stage within 7 h of release, the loaded PTX was rapidly released and the sustained release was observed for up to 48 h. In vivo studies, PTX-loaded Pluronic nanoparticles were observed with higher anti-tumor efficacy compared with PTX formulated in Cremophor EL.
KW - Anti-tumor efficacy
KW - Cancer therapy
KW - Non-invasive animal imaging
KW - Pluronic nanoparticles
KW - Temperature-induced phase transition
UR - http://www.scopus.com/inward/record.url?scp=78649775109&partnerID=8YFLogxK
U2 - 10.1016/j.jconrel.2010.08.021
DO - 10.1016/j.jconrel.2010.08.021
M3 - Article
C2 - 20797418
AN - SCOPUS:78649775109
SN - 0168-3659
VL - 148
SP - 344
EP - 350
JO - Journal of Controlled Release
JF - Journal of Controlled Release
IS - 3
ER -